Pyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic Review
Authors:
Open Access
- 20 August 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e72245
Abstract
Hand-foot syndrome (HFS) is a relatively frequent dermatologic toxic reaction to certain anti-cancer chemotherapies. The syndrome can evolve into a distressing condition that limits function and affects quality of life. Pyridoxine (vitamin B6) has been used empirically for the prevention of HFS caused by anti-cancer therapy. However, evidence of its efficacy remains controversial. Systematic literature searches were conducted on the Cochrane Library, PUBMED, EMBASE, LILACS, CBM, CNKI, VIP, WANFANG and the U.S. ClinicalTrials.gov website. We included all related randomized controlled trials (RCTs) irrespective of language. Reviewers from different professions independently assessed all potential studies and extracted data. Subgroup analysis was planned according to dose of pyridoxine. 5 RCTs involving 607 patients were contributed to the meta-analysis. No significant differences were found between patients receiving pyridoxine and placebo for prevention of incidence of HFS and grade 2 or worse HFS (relative risk (RR) 0.96, 95%confidence interval (CI) 0.86–1.06; RR0.95, 95%CI 0.73–1.24, respectively). Similarly, no significant improvement in quality of life was detected among patients. However, significant difference was found for prevention of grade 2 or worse HFS with pyridoxine 400 mg daily compared to 200 mg (RR0.55, 95%CI 0.33–0.92). There is inadequate evidence to make any recommendation about using pyridoxine for prevention of HFS caused by chemotherapy. However, pyridoxine 400 mg may have some efficacy. Further studies of large sample sizes are needed to evaluate the efficacy and safety of pyridoxine, especially at high dose, in comparison with placebo.Keywords
This publication has 24 references indexed in Scilit:
- Randomized trial of two different doses of pyridoxine in the prevention of capecitabine‐associated palmar‐plantar erythrodysesthesiaAsia-Pacific Journal of Clinical Oncology, 2010
- The hand‐foot‐syndrome associated with medical tumor therapy – classification and managementJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patientsCancer, 2010
- Unilateral hand–foot syndrome: an extraordinary side effect of capecitabineCutaneous and Ocular Toxicology, 2010
- Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and SunitinibOncology, 2009
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor TherapyClinical Cancer Research, 2009
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal of Cancer, 2008
- Management of hand-foot syndrome induced by capecitabineJournal of Oncology Pharmacy Practice, 2006
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With TaxotereJNCI: Journal of the National Cancer Institute, 1993